INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43m ago
HOUSE PTR3m ago
SEC 13F3m ago
ROBINHOOD CHAIN3m ago
Corporate insider
BA

Bachrodt Amy

SVP, FinanceCIK 0002050422

EDGAR filingsOpen in network
Disclosed transactions34
Buys / sells0 / 11
Max Insider Score29
Connections2with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
24
BA
Bachrodt AmyChief Financial Officer, 10% Owner
LYCALycia Therapeutics, Inc.
Grant or award
A—
399.7K sh
Aug 11, 2026Oct 26, 2026
traded Aug 11, 2026
+76dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Lycia Therapeutics, Inc.Chief Financial Officer, 10% Owner · Oct 26, 2026
  • Insider ofevidence
    Maze Therapeutics, Inc.SVP, Finance · Dec 31, 2025
0
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M
$26K
2,500 sh
Apr 1, 2026
Apr 2, 2026
traded Apr 1, 2026
+1d
SEC FORM 4

Evidence

0
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
2,500 sh
Apr 1, 2026Apr 2, 2026
traded Apr 1, 2026
+1dSEC FORM 4

Evidence

8
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$9,101
300 sh
Apr 1, 2026Apr 2, 2026
traded Apr 1, 2026
+1dSEC FORM 4

Evidence

15
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$65K
2,200 sh
Apr 1, 2026Apr 2, 2026
traded Apr 1, 2026
+1dSEC FORM 4

Evidence

8
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$8,830
200 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC FORM 4

Evidence

0
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$1,626
156 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC FORM 4

Evidence

3
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$50K
4,844 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC FORM 4

Evidence

0
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
156 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC FORM 4

Evidence

0
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
4,844 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC FORM 4

Evidence

12
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$34K
736 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC FORM 4

Evidence

19
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$187K
4,064 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC FORM 4

Evidence

3
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
2,503 sh
Jan 22, 2026Jan 26, 2026
traded Jan 22, 2026
+4dSEC FORM 4

Evidence

0
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$26K
2,497 sh
Jan 22, 2026Jan 26, 2026
traded Jan 22, 2026
+4dSEC FORM 4

Evidence

0
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$26K
2,503 sh
Jan 22, 2026Jan 26, 2026
traded Jan 22, 2026
+4dSEC FORM 4

Evidence

22
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$228K
5,000 sh
Jan 22, 2026Jan 26, 2026
traded Jan 22, 2026
+4dSEC FORM 4

Evidence

0
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
2,497 sh
Jan 22, 2026Jan 26, 2026
traded Jan 22, 2026
+4dSEC FORM 4

Evidence

3
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$50K
4,796 sh
Jan 2, 2026Jan 6, 2026
traded Jan 2, 2026
+4dSEC FORM 4

Evidence

0
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$2,126
204 sh
Jan 2, 2026Jan 6, 2026
traded Jan 2, 2026
+4dSEC FORM 4

Evidence

0
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
4,796 sh
Jan 2, 2026Jan 6, 2026
traded Jan 2, 2026
+4dSEC FORM 4

Evidence

0
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
204 sh
Jan 2, 2026Jan 6, 2026
traded Jan 2, 2026
+4dSEC FORM 4

Evidence

18
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$103K
2,595 sh
Jan 2, 2026Jan 6, 2026
traded Jan 2, 2026
+4dSEC FORM 4

Evidence

18
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$93K
2,405 sh
Jan 2, 2026Jan 6, 2026
traded Jan 2, 2026
+4dSEC FORM 4

Evidence

0
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$1,292
124 sh
Dec 29, 2025Dec 31, 2025
traded Dec 29, 2025
+2dSEC FORM 4

Evidence

3
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
124 sh
Dec 29, 2025Dec 31, 2025
traded Dec 29, 2025
+2dSEC FORM 4

Evidence

11
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
9,876 sh
Dec 29, 2025Dec 31, 2025
traded Dec 29, 2025
+2dSEC FORM 4

Evidence

0
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
2,395 sh
Dec 30, 2025Dec 31, 2025
traded Dec 30, 2025
+1dSEC FORM 4

Evidence

22
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$200K
5,000 sh
Dec 30, 2025Dec 31, 2025
traded Dec 30, 2025
+1dSEC FORM 4

Evidence

0
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
2,605 sh
Dec 30, 2025Dec 31, 2025
traded Dec 30, 2025
+1dSEC FORM 4

Evidence

0
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$27K
2,605 sh
Dec 30, 2025Dec 31, 2025
traded Dec 30, 2025
+1dSEC FORM 4

Evidence

0
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$25K
2,395 sh
Dec 30, 2025Dec 31, 2025
traded Dec 30, 2025
+1dSEC FORM 4

Evidence

15
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$25K
600 sh
Dec 29, 2025Dec 31, 2025
traded Dec 29, 2025
+2dSEC FORM 4

Evidence

29
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$381K
9,400 sh
Dec 29, 2025Dec 31, 2025
traded Dec 29, 2025
+2dSEC FORM 4

Evidence

14
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$103K
9,876 sh
Dec 29, 2025Dec 31, 2025
traded Dec 29, 2025
+2dSEC FORM 4

Evidence